Idiopathic Pulmonary Fibrosis Market Summary

• The IPF market size  is anticipated to witness steady growth during the forecast period (2026–2036), driven by increasing disease awareness, improvements in diagnostic capabilities, and the introduction of novel antifibrotic therapies. Advances in biomarker research, earlier diagnosis, and growing investment in treatments addressing the unmet needs of patients with progressive fibrotic lung diseases are also expected to support market expansion.
• The growing burden of IPF is associated with several factors, including population aging, smoking history, environmental and occupational exposures, and genetic susceptibility. Improved recognition and diagnosis of fibrotic interstitial lung diseases are also contributing to the identification of affected patients. The progressive nature of IPF, characterized by irreversible lung scarring, declining lung function, and an increased risk of respiratory failure, further contributes to the substantial clinical burden and complexity of long-term disease management.
• IPF prevalence increases markedly with age and is generally higher among men. A recent US claims analysis estimated crude prevalence at 46.3–88.9 per 100,000 persons. Age- and sex-adjusted prevalence ranged from 34.4–67.1 per 100,000 persons.
• The treatment landscape for IPF has evolved with the introduction of novel antifibrotic therapies. Nerandomilast (JASCAYD), a preferential phosphodiesterase 4B (PDE4B) inhibitor, represents a new therapeutic approach targeting pathways involved in inflammation and fibrosis. Approved by the US FDA in October 2025, nerandomilast has demonstrated the ability to slow lung function decline, providing an additional treatment option alongside established antifibrotic therapies such as pirfenidone and nintedanib.
• Despite advances in treatment, significant unmet needs remain in IPF management. Current therapies primarily aim to slow disease progression rather than reverse established fibrosis. There is a continued need for treatments that provide sustained disease control, preserve lung function, improve long-term clinical outcomes, and offer favorable tolerability. Additional priorities include reducing treatment burden and addressing the needs of patients across different disease stages and clinical profiles.
• The IPF treatment landscape is expected to become increasingly competitive as investigational therapies advance through clinical development. LTI-03, developed by Rein Therapeutics, represents a novel therapeutic approach targeting cellular pathways involved in lung injury and fibrosis. In 2026, the therapy received US FDA Fast Track designation for the treatment of IPF, highlighting its potential to address unmet medical needs and support the development of new treatment options beyond currently available antifibrotic therapies.
• As additional investigational therapies progress through clinical development and potentially reach the market, the IPF treatment landscape may evolve toward more diversified treatment approaches. The availability of therapies with distinct mechanisms of action could expand treatment options, address persistent unmet needs, and contribute to market growth over the forecast period.

DelveInsight's comprehensive report titled "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast – 2036" offers a detailed analysis of IPF across key epidemiological segments and patient populations. It presents historical and forecasted epidemiological data covering prevalent cases of IPF, along with severity-specific, gender-specific, and other relevant patient segments across the 7MM. The report also evaluates disease-associated complications and comorbidities, including progressive lung function decline, respiratory failure, pulmonary hypertension, acute exacerbations, and other conditions that contribute significantly to disease burden and healthcare utilization. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2026 to 2036.

The report analyzes the existing treatment practices and unmet medical requirements in IPF. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Idiopathic Pulmonary Fibrosis Disease Understanding

Idiopathic Pulmonary Fibrosis Overview

IPF is a chronic, progressive, and ultimately fatal interstitial lung disease characterized by irreversible scarring of the lung parenchyma, resulting in a gradual decline in pulmonary function. The disease is defined by a histopathological and radiological pattern of usual interstitial pneumonia (UIP) and primarily affects older adults. Although the exact cause remains unknown, IPF is believed to arise from repeated microinjury to the alveolar epithelium in genetically susceptible individuals, leading to aberrant wound-healing responses, excessive fibroblast activation, and progressive extracellular matrix deposition. Patients typically present with exertional dyspnea, persistent dry cough, reduced exercise tolerance, and worsening respiratory impairment, which contribute substantially to morbidity and mortality.

Idiopathic Pulmonary Fibrosis Diagnosis

The diagnosis of IPF requires a comprehensive clinical evaluation aimed at excluding known causes of interstitial lung disease and identifying a UIP pattern on high-resolution computed tomography (HRCT) or lung histopathology when necessary. Diagnostic assessment typically includes detailed medical history, physical examination, pulmonary function testing, HRCT imaging, serologic testing to exclude connective tissue disease, and multidisciplinary discussion involving pulmonologists, radiologists, and pathologists. Because disease presentation may overlap with other fibrotic interstitial lung diseases, accurate and timely diagnosis is essential for disease characterization, prognostic assessment, and appropriate patient management.

Further details related to country-based variations are provided in the report...

Current Idiopathic Pulmonary Fibrosis Treatment Landscape

According to current clinical practice, IPF management focuses on slowing disease progression, preserving lung function, relieving symptoms, and maintaining quality of life. Approved antifibrotic therapies include nintedanib, pirfenidone, and JASCAYD, with nerandomilast, a preferential PDE4B inhibitor, expanding the treatment landscape following its FDA approval in October 2025. Supportive care includes pulmonary rehabilitation, supplemental oxygen when indicated, vaccination, smoking cessation, and management of comorbidities, while lung transplantation may be considered in eligible patients with advanced disease.

Despite these advances, IPF remains associated with substantial morbidity and mortality due to its progressive and irreversible fibrotic course. Corticosteroids and immunosuppressive agents are generally not recommended for chronic IPF but may be used in selected settings such as acute exacerbations or concomitant autoimmune disease. Significant unmet needs remain for therapies that can more effectively control fibrosis, preserve lung function, reduce acute exacerbations, improve quality of life, and extend survival.

Further details related to country-based variations are provided in the report...

Idiopathic Pulmonary Fibrosis Epidemiology

The Idiopathic Pulmonary Fibrosis epidemiology of the market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The patient pool, their trends, and the underlying assumptions are all included in this section of the report. This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of IPF. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Idiopathic Pulmonary Fibrosis Epidemiology Key Findings

• Amongst EU4, the prevalence of IPF in Spain is estimated at 21.5 cases per 100,000 inhabitants based on a population registry study, while the annual prevalence of IPF in Italy was estimated at 25.6 per 100,000 using ICD9-CM code.
• The prevalence of IPF in Japan is 27 per 100,000 population based on a nationwide claims database analysis, with an earlier epidemiological survey (2003–2007) indicating 10 per 100,000 population.
• Major factors contributing to regional differences in the prevalence and burden of IPF across the 7MM include variations in demographic characteristics, smoking prevalence, environmental and occupational risk factors, healthcare access, and disease recognition. The epidemiology of IPF is expected to evolve during the forecast period (2026–2036), supported by an aging population, improved diagnosis of interstitial lung diseases, increasing awareness among healthcare professionals, and continued refinement of diagnostic criteria.

Idiopathic Pulmonary Fibrosis Epidemiology Segmentation

• Total Diagnosed Prevalent Cases of IPF
• Gender-specific Diagnosed Prevalent Cases of IPF
• Age-specific Diagnosed Prevalent Cases of IPF
• Severity-specific Diagnosed Prevalent Cases of IPF
• Total Treated Cases of IPF

Further details related to country-based variations are provided in the report...

Idiopathic Pulmonary Fibrosis Drug Chapters

The Idiopathic Pulmonary Fibrosis drug chapter segment of the Idiopathic Pulmonary Fibrosis report encloses the detailed analysis of Idiopathic Pulmonary Fibrosis marketed drugs and late-stage (Phase-III and Phase-II) Idiopathic Pulmonary Fibrosis pipeline drugs. It also helps to understand the Idiopathic Pulmonary Fibrosis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Approved Therapies for Idiopathic Pulmonary Fibrosis

Nerandomilast (JASCAYD): Boehringer Ingelheim

Nerandomilast (JASCAYD) is an oral preferential phosphodiesterase 4B (PDE4B) inhibitor approved for the treatment of IPF. By selectively inhibiting PDE4B, nerandomilast modulates inflammatory and fibrotic pathways implicated in disease progression, with the goal of slowing lung function decline. Clinical studies have demonstrated its ability to reduce the rate of forced vital capacity (FVC) decline while maintaining a manageable safety profile. Common adverse events include gastrointestinal disturbances such as diarrhea and nausea, which are generally consistent with the known effects of PDE4 inhibition.

• In May 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of JASCAYD for the treatment of IPF and progressive pulmonary fibrosis (PPF) in the European Union. The recommendation was supported by data from the Phase III FIBRONEER clinical program, which evaluated the efficacy and safety of nerandomilast in patients with IPF and PPF.
• In May 2026, Japan’s Ministry of Health, Labour and Welfare (MHLW) approved JASCAYD for the treatment of adults with IPF and PPF. The approval marked the availability of the first oral preferential PDE4B inhibitor authorized for use in IPF and PPF, providing a new treatment option for patients with progressive fibrotic lung diseases.

Note: Detailed marketed therapies assessment will be provided in the final report...

Idiopathic Pulmonary Fibrosis Pipeline Analysis

The IPF market is expected to evolve gradually, driven by a growing number of emerging therapies currently in clinical development. Key players such as Bristol Myers Squibb (Admilparant), and Syndax Pharmaceuticals axatilimab, among others, are showing active commitment to addressing this unmet need, with ongoing efforts to advance novel treatment options for this complex and heterogeneous allergic condition.

Admilparant: Bristol Myers Squibb

Admilparant is an investigational oral lysophosphatidic acid receptor 1 (LPA1) antagonist being developed by Bristol Myers Squibb for the treatment of IPF. By inhibiting LPA1 signaling, admilparant is designed to modulate key pathways involved in fibroblast recruitment, tissue remodeling, and progressive pulmonary fibrosis. The therapy aims to slow disease progression and preserve lung function by targeting mechanisms implicated in fibrotic lung injury. Clinical development of admilparant reflects ongoing efforts to expand disease-modifying treatment options for patients with IPF and other fibrotic interstitial lung diseases.

• In 2026, Bristol Myers Squibb initiated plans for a Phase III, open-label, long-term extension study of admilparant in patients with pulmonary fibrosis who have completed the parent ALOFT-IPF or PPF studies. The study is expected to begin in December 2026 and will evaluate the long-term safety and tolerability of admilparant.

Axatilimab (NIKTIMVO): Syndax Pharmaceuticals

NIKTIMVO is a monoclonal antibody targeting the colony-stimulating factor 1 receptor (CSF-1R), being developed by Syndax Pharmaceuticals for fibrotic diseases, including IPF. By inhibiting CSF-1R signaling, NIKTIMVO is designed to modulate macrophage-mediated inflammatory and fibrotic pathways that contribute to tissue remodeling and fibrosis progression. The therapy is being evaluated for its potential to slow disease progression and address key mechanisms underlying fibrotic lung disease.

• In February 2026, Syndax Pharmaceuticals reported completion of patient enrollment in MAXPIRe, a Phase II, 26-week, randomized, double-blind, placebo-controlled study evaluating axatilimab on top of standard of care in patients with IPF. The study enrolled approximately 145 participants and is evaluating the annualized rate of FVC decline over 26 weeks as the primary endpoint. Topline data are expected in Q4 2026.

Idiopathic Pulmonary Fibrosis Market Outlook

The IPF therapeutics market is further expected to increase by the major drivers, such as the rising prevalent population, technological advancements, and upcoming therapies in the forecast period (2026–2036).

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the IPF market in the 7MM is expected to change significantly during the forecast period 2026-2036.

Idiopathic Pulmonary Fibrosis Drug Analysis & Competitive Landscape

The IPF drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the IPF treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the IPF therapeutics market.

Note: Detailed emerging therapies assessment will be provided in the final report...

Idiopathic Pulmonary Fibrosis Market Segmentation

DelveInsight's 'Idiopathic Pulmonary Fibrosis – Market Insights, Epidemiology, and Market Forecast – 2036’ report provides a detailed outlook of the current and future IPF market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Idiopathic Pulmonary Fibrosis Market Size by Countries

The IPF market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2025, the United States held a significant share of the overall 7MM (Seven Major Markets) IPF market, primarily attributed to the country's higher diagnosed Prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Idiopathic Pulmonary Fibrosis (IPF) Market Size by Therapies

IPF Market Size by Therapies is categorized into current and emerging markets for the study period 2022–2036.

Note: Detailed market segment assessment will be provided in the final report...

Recent Development

In Sep 2026, Daewoong Pharmaceutical presented baseline characteristics from 104 patients enrolled in its global Phase 2 trial of Bersiporocin at the European Respiratory Society (ERS) Congress. Bersiporocin is a first-in-class, selective prolyl-tRNA synthetase (PRS) inhibitor designed to treat idiopathic pulmonary fibrosis (IPF) by inhibiting excessive collagen synthesis. The trial cohort, recruited across sites in the U.S. and South Korea, includes both antifibrotic-treated and untreated patients. The presentation highlights steady clinical progress, with topline safety and efficacy data anticipated in the first half of 2027.

Idiopathic Pulmonary Fibrosis Drugs Uptake

This section focuses on the sales uptake of potential of Idiopathic Pulmonary Fibrosis drugs that have recently been launched or are anticipated to be launched in the IPF market between 2022 and 2036. It estimates the market penetration of IPF drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the IPF market.

The emerging IPF therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the IPF market.

Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on Idiopathic Pulmonary Fibrosis (IPF).

Idiopathic Pulmonary Fibrosis Market Access and Reimbursement

DelveInsight’s ‘Idiopathic Pulmonary Fibrosis – Market Insights, Epidemiology, and Market Forecast – 2036’ report provides a descriptive overview of the market access and reimbursement scenario of IPF.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

Idiopathic Pulmonary Fibrosis Report KOL Views

To keep up with current IPF market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in IPF domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or IPF market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the IPF unmet needs.

Idiopathic Pulmonary Fibrosis: KOL Insights

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as National Jewish Health, Charité – Universitätsmedizin Berlin, Hospital Clínic de Barcelona, Humanitas Research Hospital, Hôpital Européen Georges-Pompidou, Royal Brompton Hospital, and Jikei University Hospital among others.

Note: Detailed assessment of KOL Views will be provided in the full report on Idiopathic Pulmonary Fibrosis (IPF)...

Idiopathic Pulmonary Fibrosis Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the IPF market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Idiopathic Pulmonary Fibrosis Development Activities

The Idiopathic Pulmonary Fibrosis pipeline report offers an analysis of therapeutic candidates in Phase I/II and III stages and examines companies involved in developing targeted therapeutics for IPF. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Idiopathic Pulmonary Fibrosis Pipeline Development Activities

The Idiopathic Pulmonary Fibrosis clinical trial analysis report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging IPF therapies.

Idiopathic Pulmonary Fibrosis Market Report Insights

• Idiopathic Pulmonary Fibrosis Patient Population
• Idiopathic Pulmonary Fibrosis Therapeutic Approaches
• Idiopathic Pulmonary Fibrosis Pipeline Analysis
• Idiopathic Pulmonary Fibrosis Market Size and Trends
• Idiopathic Pulmonary Fibrosis Market Opportunities
• Impact of Upcoming Idiopathic Pulmonary Fibrosis Therapies

Idiopathic Pulmonary Fibrosis Market Report Key Strengths

• 11 Years Forecast
• The 7MM Coverage
• Idiopathic Pulmonary Fibrosis Epidemiology Segmentation
• Competitive Landscape
• Highly Analyzed Idiopathic Pulmonary Fibrosis Market
• Idiopathic Pulmonary Fibrosis Drugs Uptake

Idiopathic Pulmonary Fibrosis Market Report Assessment

• Idiopathic Pulmonary Fibrosis Current Treatment Practices
• Idiopathic Pulmonary Fibrosis Unmet Needs
• Idiopathic Pulmonary Fibrosis Pipeline Product Profiles
• Idiopathic Pulmonary Fibrosis Market Attractiveness
• Idiopathic Pulmonary Fibrosis Market Drivers
• Idiopathic Pulmonary Fibrosis Market Barriers

Key Questions Related to the Idiopathic Pulmonary Fibrosis Market Report:

• How common is IPF?
• What are the key findings of IPF epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2022–2036)?
• What are the currently available treatments for IPF?
• What are the disease risk, burden, and unmet needs of IPF?
• At what CAGR is the IPF market and its epidemiology is expected to grow in the 7MM during the forecast period (2026–2036)?
• How would the unmet needs impact the IPF market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of IPF in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of Idiopathic Pulmonary Fibrosis patients during the forecast period (2026–2036)?
• How many companies are currently developing therapies for the treatment of IPF?

Reasons to buy Idiopathic Pulmonary Fibrosis Market Forecast Report

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the IPF market.
• Insights on patient burden/disease Prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.